NFA
CHRS icon

Nationwide Fund Advisors’s Coherus Oncology CHRS Stock Holding History

Nationwide Fund Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-47,741
Closed -$637K – 391
2017
Q3 		$637K Hold
47,741
– – ﹤0.01% 2055
2017
Q2 		$685K Buy
47,741
+13,759
+40% +$265K ﹤0.01% 2005
2017
Q1 		$719K Buy
33,982
+421
+1% +$10.4K ﹤0.01% 1948
2016
Q4 		$945K Sell
33,561
-3,270
-9% -$91.5K ﹤0.01% 1819
2016
Q3 		$986K Buy
36,831
+386
+1% +$10.5K ﹤0.01% 1799
2016
Q2 		$616K Buy
36,445
+21,713
+147% +$408K ﹤0.01% 2039
2016
Q1 		$328K Sell
14,732
-715
-5% -$11.7K ﹤0.01% 2301
2015
Q4 		$355K Buy
15,447
+215
+1% +$5.53K ﹤0.01% 2274
2015
Q3 		$305K Hold
15,232
– – ﹤0.01% 2363
2015
Q2 		$440K Buy
15,232
+10,236
+205% +$259K ﹤0.01% 2317
2015
Q1 		$153K Buy
4,996
+229
+5% +$5.92K ﹤0.01% 2823
2014
Q4 		$78K Buy
+4,767
New +$67.3K ﹤0.01% 2966

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Nationwide Fund Advisors's CHRS Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Coherus Oncology (CHRS) in Q4 2017, closing a stake of 47,741 shares — an estimated $637K sold.

Nationwide Fund Advisors first reported a position in CHRS in Q4 2014 and held it in 12 quarters. The position peaked at $986K in Q3 2016. 94 funds tracked by Wall St. Rank hold CHRS as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Coherus Oncology position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 47,741 Coherus Oncology shares in Q4 2017, an estimated $637K.
  • Nationwide Fund Advisors first reported a position in Coherus Oncology in Q4 2014 and held it in 12 quarters.
  • Nationwide Fund Advisors's Coherus Oncology position peaked at $986K in Q3 2016.
  • 94 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.